More Post from the Author
- Keys Inc. Marks a Strong First Half of 2025 with New Features and Industry Growth
- ITRI Advances Taiwan's 6G Global Partnerships in the EU and the UK
- Global Times: 'Our pursuit of modern economic development must be underpinned by strategic foresight and holistic coordination'
- Yingfa Ruineng, Srdrlebilirlik Yoluyla Fotovoltaik Sektrne Liderlik Etmeyi Hedefleyerek BM Kresel lkeler Szlemesine Katld
- BUTLER NATIONAL CORPORATION ANNOUNCES FISCAL YEAR END 2025 FINANCIAL RESULTS
Indivior Statement RE: Delayed FDA Approval of SUBLOCADE Label Changes
Published on Wed 12 Feb 2025 8:07:04 UTC
RICHMOND, Va., Feb. 12, 2025 /PRNewswire/ --Indivior PLC (Nasdaq/LSE: INDV)provides the following update regarding its PDUFA action date for label changes (rapid initiation protocol and alternative injection sites) for SUBLOCADE (buprenorphine extended-release) Injection, which was scheduled for February 7, 2025:
Yesterday, February 11th, the FDA informed Indivior that, following acceptance of the proposed label for SUBLOCADE, there were no outstanding items to address, but that final review of the SUBLOCADE label changes has been delayed.
Indivior will provide further updates on the status of the approval of the proposed SUBLOCADE label changes as appropriate.
SOURCE Indivior PLC
More Post from the Author
- Keys Inc. Marks a Strong First Half of 2025 with New Features and Industry Growth
- ITRI Advances Taiwan's 6G Global Partnerships in the EU and the UK
- Global Times: 'Our pursuit of modern economic development must be underpinned by strategic foresight and holistic coordination'
- Yingfa Ruineng, Srdrlebilirlik Yoluyla Fotovoltaik Sektrne Liderlik Etmeyi Hedefleyerek BM Kresel lkeler Szlemesine Katld
- BUTLER NATIONAL CORPORATION ANNOUNCES FISCAL YEAR END 2025 FINANCIAL RESULTS